Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling

[1]  H. Redmond,et al.  Activation of the TLR2-mediated downstream signaling pathways NF-κB and MAPK is responsible for B7-H3-augmented inflammatory response during S. pneumoniae infection , 2017, Journal of Neuroimmunology.

[2]  Xueping Chen,et al.  TLR2 mediates autophagy through ERK signaling pathway in Mycoplasma gallisepticum‐infected RAW264.7 cells , 2017, Molecular immunology.

[3]  S. Rose-John,et al.  The role of IL-6 in host defence against infections: immunobiology and clinical implications , 2017, Nature Reviews Rheumatology.

[4]  Toshio Tanaka,et al.  The role and therapeutic targeting of IL-6 in rheumatoid arthritis , 2017, Expert review of clinical immunology.

[5]  S. Heink.  Multiple Sklerose: Neu entdeckter Signalmechanismus macht T-Zellen pathogen , 2017 .

[6]  S. Rose-John,et al.  Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation , 2017, PLoS biology.

[7]  H. Blum,et al.  Trans-presentation of interleukin-6 by dendritic cells is required for priming pathogenic TH17 cells , 2016, Nature Immunology.

[8]  S. Rose-John,et al.  Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17 , 2016, Scientific Reports.

[9]  A. Chalaris,et al.  ADAM17 controls IL‐6 signaling by cleavage of the murine IL‐6Rα from the cell surface of leukocytes during inflammatory responses , 2016, Journal of leukocyte biology.

[10]  A. Mansell,et al.  Toll-like receptors: the swiss army knife of immunity and vaccine development , 2016, Clinical & translational immunology.

[11]  Manuel A. R. Ferreira,et al.  Allergen-induced IL-6 trans-signaling activates γδ T cells to promote type 2 and type 17 airway inflammation. , 2015, The Journal of allergy and clinical immunology.

[12]  A. Chalaris,et al.  Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles* , 2015, The Journal of Biological Chemistry.

[13]  S. Rose-John,et al.  The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. , 2015, Current opinion in immunology.

[14]  J. Hampe,et al.  IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans[S] , 2015, Journal of Lipid Research.

[15]  C. Hunter,et al.  IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.

[16]  N. Weiler,et al.  The wingless‐related integration site‐5a/secreted frizzled‐related protein‐5 system is dysregulated in human sepsis , 2015, Clinical and experimental immunology.

[17]  Stefan Rose-John,et al.  IL-6 biology: implications for clinical targeting in rheumatic disease , 2014, Nature Reviews Rheumatology.

[18]  S. Rose-John,et al.  Interleukin-6 and its receptors: a highly regulated and dynamic system. , 2014, Cytokine.

[19]  J. Scheller,et al.  The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. , 2014, Biochimica et biophysica acta.

[20]  Toshio Tanaka,et al.  The Biology and Medical Implications of Interleukin-6 , 2014, Cancer Immunology Research.

[21]  J. Scheller,et al.  Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. , 2014, Seminars in immunology.

[22]  B. Jenkins,et al.  Dangerous liaisons between interleukin-6 cytokine and toll-like receptor families: a potent combination in inflammation and cancer. , 2013, Cytokine & growth factor reviews.

[23]  J. Scheller,et al.  Minimal Interleukin 6 (IL-6) Receptor Stalk Composition for IL-6 Receptor Shedding and IL-6 Classic Signaling , 2013, The Journal of Biological Chemistry.

[24]  A. Parker,et al.  STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. , 2012, Cancer cell.

[25]  H. Hermanns,et al.  Plasticity and cross-talk of interleukin 6-type cytokines. , 2012, Cytokine & growth factor reviews.

[26]  R. Derynck,et al.  TACE Activation by MAPK-Mediated Regulation of Cell Surface Dimerization and TIMP3 Association , 2012, Science Signaling.

[27]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[28]  J. Scheller,et al.  The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. , 2011, European journal of cell biology.

[29]  K. Horiuchi,et al.  Leukocyte ADAM17 Regulates Acute Pulmonary Inflammation , 2011, PloS one.

[30]  J. Scheller,et al.  Species Specificity of ADAM10 and ADAM17 Proteins in Interleukin-6 (IL-6) Trans-signaling and Novel Role of ADAM10 in Inducible IL-6 Receptor Shedding* , 2011, The Journal of Biological Chemistry.

[31]  T. Meyer,et al.  Differential but Direct Abolishment of Human Regulatory T Cell Suppressive Capacity by Various TLR2 Ligands , 2010, The Journal of Immunology.

[32]  R. Derynck,et al.  Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. , 2010, Molecular cell.

[33]  M. Rincón,et al.  Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells1 , 2008, The Journal of Immunology.

[34]  K. Horiuchi,et al.  Cutting Edge: TNF-α-Converting Enzyme (TACE/ADAM17) Inactivation in Mouse Myeloid Cells Prevents Lethality from Endotoxin Shock1 , 2007, The Journal of Immunology.

[35]  S. Bandinelli,et al.  A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects , 2007, Genes and Immunity.

[36]  N. Gay,et al.  Structure and function of Toll receptors and their ligands. , 2007, Annual review of biochemistry.

[37]  K. Horiuchi,et al.  TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock , 2007 .

[38]  S. Rose-John,et al.  Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells. , 2006, International immunology.

[39]  Michael Krawczak,et al.  PopGen: Population-Based Recruitment of Patients and Controls for the Analysis of Complex Genotype-Phenotype Relationships , 2006, Public Health Genomics.

[40]  K. Akazawa,et al.  Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced , 2004, Genes and Immunity.

[41]  Stefan Rose-John,et al.  Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)* , 2003, Journal of Biological Chemistry.

[42]  P. Godowski,et al.  Toll-like receptor 2–mediated NF-κB activation requires a Rac1-dependent pathway , 2000, Nature Immunology.

[43]  P. Godowski,et al.  Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. , 2000, Nature immunology.

[44]  W. Rom,et al.  Activation of the interleukin 6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Heinrich,et al.  Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. , 1992, Biochemical and biophysical research communications.

[46]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .